Palmer, Christine D. http://orcid.org/0000-0003-3213-0398
Rappaport, Amy R.
Davis, Matthew J.
Hart, Meghan G.
Scallan, Ciaran D.
Hong, Sue-Jean
Gitlin, Leonid
Kraemer, Lauren D.
Kounlavouth, Sonia
Yang, Aaron
Smith, Lindsey
Schenk, Desiree
Skoberne, Mojca
Taquechel, Kiara http://orcid.org/0000-0001-8902-4305
Marrali, Martina
Jaroslavsky, Jason R.
Nganje, Charmaine N.
Maloney, Elizabeth http://orcid.org/0000-0002-5023-8573
Zhou, Rita
Navarro-Gomez, Daniel
Greene, Adrienne C.
Grotenbreg, Gijsbert
Greer, Renee
Blair, Wade http://orcid.org/0000-0002-2672-5136
Cao, Minh Duc
Chan, Shawn
Bae, Kyounghwa
Spira, Alexander I.
Roychowdhury, Sameek
Carbone, David P. http://orcid.org/0000-0003-3002-1921
Henick, Brian S.
Drake, Charles G.
Solomon, Benjamin J.
Ahn, Daniel H.
Mahipal, Amit
Maron, Steve B. http://orcid.org/0000-0002-8794-130X
Johnson, Benny
Rousseau, Raphael
Yelensky, Roman http://orcid.org/0000-0002-5356-0111
Liao, Chih-Yi
Catenacci, Daniel V. T.
Allen, Andrew
Ferguson, Andrew R.
Jooss, Karin
Article History
Received: 4 March 2022
Accepted: 6 July 2022
First Online: 15 August 2022
Competing interests
: C.D.P., A.R.R., M.G.H., C.D.S., L.G., S-.J.H., L.D.K., S.K., D.S., M.D., M.M., J.R.J., C.N.N., R.Z., D.N.G., A.C.G., M.D.C., S.C., K.B., R.R., A.A., A.R.F., K.J., A.Y., L.S., M.S., K.T., E.M., G.G., R.G., W.B. and R.Y. are stockholders and either current or previous employees at Gritstone bio and may be listed as co-inventors on various pending patent applications related to the vaccine platform presented in this study. D.V.T.C. consults/has consulted/has advisory/had advisory roles at Genentech/Roche, Eli Lilly, Merck, Daiichi Sankyo, BMS, Ono, Five Prime, Seattle Genetics, Amgen, Taiho, Astellas, Gritstone bio, Pieris, Zymeworks, Basilea, QED, Foundation Medicine, Pierian, Silverback Therapeutics, Servier, Blueprint Medicines, Arcus Biosciences, Tempus, Guardant Health, Archer and Natera. C.G.D. is currently employed by Janssen R&D. B.S.H. has/had consultant/advisory roles for AstraZeneca, Ideaya, Jazz Pharmaceuticals, and research support from Neximmune. B.J.S. consults/has consulted/had advisory roles for Bristol Myers Squibb, Merck Sharp & Dohme, AstraZeneca, Pfizer, Roche/Genentech, Amgen, Lilly, Sanofi-Regeneron, Glaxo-Smith Kline, Takeda, Novartis and Beigene; has received honoria from Bristol Myers Squibb, Merck Sharp & Dohme, AstraZeneca, Pfizer, Roche/Genentech, Amgen, Lilly, Sanofi-Regeneron, Glaxo-Smith Kline, Takeda, Novartis and Beigene; has received research funding from Sanofi-Regeneron; and has received royalties from UpToDate. B.J. consulted for/had advisory roles with Taiho Oncology, Insmed Oncology, Gritstone bio, Pfizer and Incyte and received research funding from Gateway for Cancer Research, Bristol Myers Squibb and Syntrix. A.M. is on the Advisory Board for AstraZeneca, QED, and Taiho Oncology. S.R. participated in Advisory Boards for Incyte Corporation (2017), AbbVie (2017), QED Therapeutics (2018, 2019) and Bayer (2020) (healthcare companies <10,000 USD). S.R. received honoraria from IDT (2017) and Illumina (2018) (technology companies). S.R. received consulting fees from QED Therapeutics (2018, 2019) and Merck (2019) (healthcare companies <10,000 USD). S.R. received travel reimbursement from Incyte Corporation (2019) (<999 USD). C.Y.L. received honoraria from Cancer Experts Now and has consulting/advisory board roles with Transthera, BluePrints Medicine, Genentech, QED Therapeutics, Histosonics and Ipsen and is part of the Speaker’s Bureau for Eisai and Incyte. S.B.M. received honoraria from Natera, Bicara, Novartis, Basilea and Daiichi Sankyo and owned stock in Calithera outside the submitted work. The remaining authors declare no competing interests.
Free to read: This content has been made available to all.